// App-Quantinova.ai

: Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma

Researchers

Presenter

  • Ola Landgren

Principal Investigators

  • Dickran Kazandjian

  • Ashleigh O'Connell

  • Gregory Finn

  • Noopur Raje

Medical Centers

  • Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

Locations

  • United States

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Autoimmune (AI)

  • Genetic Disorder

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Graft-versus-host disease

  • Cytokine release syndrome

  • Primary plasma cell leukemia

  • Multiple Myeloma

  • POEMS syndrome

  • Amyloid disease

  • Lymphomas

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • PF-03084014

  • Lanthanum carbonate

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Tolerability

  • Immunogenicity

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved